{"schema_version":"secwatch.filing_event.v1","accession":"0001828185-25-000071","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2025-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.655809+00:00","generated_at":"2026-05-16T23:07:26.674223+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Barinthus Bio Q3 net loss $14.6M; all-stock merger with Clywedog","bullets":["Net loss of $14.6M ($0.36/share) in Q3 2025 vs $21.1M loss in Q2 2025.","Cash and equivalents $75.7M as of Sept 30, down $12.1M from June 30; runway into 2027.","Announced all-stock merger with Clywedog; combined company renamed Clywedog Therapeutics Holdings, ticker CLYD, close expected H1 2026.","VTP-1000 celiac SAD data expected by end 2025; MAD data in H2 2026.","Impairment of $4.7M due to deal valuation; R&D expenses fell to $5.4M from $8.0M QoQ."],"urls":{"canonical":"https://secwatch.observer/filing/0001828185-25-000071","json":"https://secwatch.observer/filing/0001828185-25-000071.json","markdown":"https://secwatch.observer/filing/0001828185-25-000071.md","text":"https://secwatch.observer/filing/0001828185-25-000071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000182818525000071/0001828185-25-000071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000182818525000071/brns-20251107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:07:26.674223+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}